Sexual Health and Hormone Peptides: Monographs

PT-141 (bremelanotide) is the only FDA-approved entry here; the remainder are research-stage or prescribed off-label.

PT-141 (bremelanotide) is the only FDA-approved entry here; the remainder are research-stage or prescribed off-label.

Peptides covered in this chapter

Gonadorelin, Kisspeptin-10, Prostamax, PT-141 (bremelanotide), TRH Thyrotropin (Protirelin), Triptorelin (GnRH)

Gonadorelin

Timelines for Effect : Initial hormonal changes may be observed within weeks, with more significant effects developing over months.

Regulatory status

• Gonadorelin is not FDA-approved for any clinical indication as of March 2026. Its regulatory classification is “research use only.”
• Compounding pharmacies cannot legally dispense gonadorelin to patients for clinical use under current FDA guidance — it does not appear on the FDA’s 503A or 503B bulk drug substance lists as an approved compoundable substance.
• Gonadorelin is not a DEA-controlled substance, meaning possession alone doesn’t carry the same criminal exposure as Schedule I or II drugs — but selling or distributing unapproved drug products still violates federal law.

Dosing

• Standard Dosage Range : Typically, Gonadorelin is administered in micrograms (mcg) with specific ranges depending on the form and purpose.
• Administration Method : Most commonly administered via subcutaneous injection, but other forms like intramuscular and intranasal are also used.
• Typical Cycle Length : Treatment cycles can vary from a few weeks to several months, depending on the therapeutic goal.
• Regulatory Status : Gonadorelin is not FDA-approved for general medical use and is available for research purposes only.

Common side effects

• Gonadorelin is not FDA-approved and is available for research purposes only.
• Common side effects include headache, nausea, and flushing.
• Serious side effects can include hypersensitivity reactions and pituitary apoplexy.

Results and timeline

• Timelines for Effect : Initial hormonal changes may be observed within weeks, with more significant effects developing over months.
• Outcome Variability : Results vary based on dosing compliance, lifestyle factors, and individual physiological differences.
• Clinical Context : Gonadorelin is primarily used for research on endocrine feedback and hypothalamic-pituitary axis regulation.

Data points extracted from source articles: Reported dose figures: 100-200 mcg, 100-500 mcg, 200-400 mcg, 200-500 mcg, 100-300 mcg · Routes mentioned: subcutaneous, intramuscular

Kisspeptin-10

Dosing

• Standard Dosage Range : Typically administered subcutaneously in dosages ranging from 100 mcg to 300 mcg per injection.
• Administration Method : Primarily subcutaneous injection due to its bioavailability and targeted delivery.
• Typical Cycle Length : Cycles generally last 4-12 weeks, depending on therapeutic goals.
• Regulatory Status : Classified as a research peptide, not FDA-approved for clinical use.

Data points extracted from source articles: Reported dose figures: 100 mcg, 300 mcg, 200 mcg, 150 mcg, 100-200 mcg · Routes mentioned: subcutaneous, intramuscular

Prostamax

Dosing

• Standard Dosage Range : Prostamax is typically administered in microgram (mcg) doses due to its potent activity.
• Administration Method : Available as a lyophilized powder for research use; requires reconstitution before administration.
• Typical Cycle Length : Usage cycles can vary, but many research protocols suggest cycles of 4-6 weeks.
• Regulatory Status : Prostamax is not FDA-approved and is available for research purposes only.

Common side effects

• Prostamax is not FDA-approved and remains available for research purposes only, with limited human safety data compared to approved peptide therapeutics
• Chromatin-related effects occur at concentrations as low as 0.05 ng/ml in tissue culture studies, with thermal denaturation temperature shifts of 2.9°C observed in lymphocyte studies
• Lymphocyte activation and heterochromatin decondensation represent the most documented biological effects, occurring within 24-48 hours of exposure in cellular studies

Cost and access

• Prostamax is available for research purposes only, not approved by the FDA for human therapeutic use, which significantly affects pricing and availability
• Research-grade Prostamax typically costs $150-$400 per 10mg vial from licensed research compound suppliers
• Clinical research programs involving Prostamax range from $300-$800 monthly, including monitoring and administration protocols

Data points extracted from source articles: Reported dose figures: 75 mcg, 50 to 100 mcg, 50-100 mcg, 100 mcg, 50 mcg · Routes mentioned: subcutaneous, intramuscular · Price points: $300, $50, $800, $100

PT-141 (bremelanotide)

Also written as: PT-141, pt-141

PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women but is used off-label for men.

Dosing

• Standard Dosage Range : PT-141 is typically administered at doses ranging from 1.75 mg to 3.0 mg per use.
• Administration Method : Subcutaneous injection is the most common route due to its direct absorption and efficacy.
• Typical Cycle Length : PT-141 is often used on an on-demand basis rather than fixed cycles, especially for hypoactive sexual desire disorder.
• Regulatory Status : PT-141, also known as bremelanotide , is FDA-approved for treating hypoactive sexual desire disorder in premenopausal women.

Common side effects

• PT-141 (bremelanotide) is not FDA-approved and is available for research purposes only.
• Common side effects include nausea, flushing, and headache, as reported in clinical trials.
• Serious side effects can include increased blood pressure and cardiovascular issues.

Results and timeline

• PT-141 is FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
• Clinical trials indicate that many patients notice effects within hours, with continued improvement over weeks.
• Factors such as dosing compliance, lifestyle, and individual health can influence outcomes.

Cost and access

• PT-141 (bremelanotide) is not FDA-approved and is available only for research purposes, significantly affecting pricing and access
• Research-grade PT-141 typically costs $150-$400 per month through specialized research compound suppliers
• Consultation fees with peptide therapy clinics range from $200-$500 for initial evaluations

Data points extracted from source articles: Reported dose figures: 1.75 mg, 3.0 mg, 2.25 mg, 2.5 mg, 100 mcg · Routes mentioned: subcutaneous, oral, nasal · Price points: $400, $800, $150, $300

TRH Thyrotropin (Protirelin)

Dosing

• TRH Thyrotropin (Protirelin) is available for research purposes only and is not FDA-approved for therapeutic use
• Research protocols typically use intravenous doses ranging from 200-500 mcg, with some studies using up to 1000 mcg
• Standard administration involves single bolus injections, with response measured at 15, 30, 45, and 60 minutes post-injection
• Dose-response studies demonstrate that TSH and prolactin responses plateau at doses above 400 mcg in most subjects

Common side effects

• TRH Thyrotropin (Protirelin) is currently available for research purposes only and lacks FDA approval for therapeutic use
• Common side effects in clinical studies include transient nausea (15-25% of subjects), mild cardiovascular effects (5-10%), and injection site reactions (10-15%)
• Dose-dependent effects occur with higher frequencies at doses above 0.1 mg/kg intravenously, based on veterinary and human research data

Data points extracted from source articles: Reported dose figures: 400 mcg, 500 mcg, 200-500 mcg, 200-300 mcg, 1000 mcg · Routes mentioned: intravenous, subcutaneous, nasal

Triptorelin (GnRH)

Dosing

• Standard Dosage Range : Triptorelin (GnRH) is typically administered in doses ranging from 0.1 mg to 3.75 mg, depending on the therapeutic goal and administration form.
• Administration Method : Triptorelin is commonly administered via intramuscular or subcutaneous injection, with frequency varying from daily to monthly.
• Typical Cycle Length : Treatment cycles can vary widely, often ranging from several weeks to several months, depending on the condition being treated.
• Regulatory Status : Triptorelin is not FDA-approved and is available for research purposes only. It is essential to use under medical supervision.

Data points extracted from source articles: Reported dose figures: 3.75 mg, 0.1 mg, 11.25 mg, 0.5 mg · Routes mentioned: intramuscular, subcutaneous

This article is part of the Peptide Therapy Complete Guide

• Chapter 1. What Is Peptide Therapy? A Plain-English Foundation
• Chapter 2. How Peptides Work: Mechanisms of Action by Class
• Chapter 3. Is Peptide Therapy Safe? Side Effects, Interactions and Long-Term Data
• Chapter 4. The Legal and Regulatory Landscape for Peptides in the United States
• Chapter 5. FDA Compounding Decisions and the 2026 Peptide Rulemaking
• Chapter 6. Dosing Principles: How Peptide Protocols Are Actually Built
• Chapter 7. Side Effects Across Peptides: Patterns, Routes and Management
• Chapter 8. What Results to Expect, and When
• Chapter 9. Cost, Insurance and Access: What Peptide Therapy Actually Costs
• Chapter 10. Reconstitution, Administration and Handling
• Chapter 11. How to Choose a Peptide Therapy Clinic
• Chapter 12. Telehealth Peptide Therapy: How Remote Access Works
• Chapter 13. Clinical Protocols and Stacks
• Chapter 14. Weight Loss and Metabolic Peptides: Monographs
• Chapter 15. Growth Hormone and Performance Peptides: Monographs
• Chapter 16. Tissue Repair and Healing Peptides: Monographs
• Chapter 17. Longevity and Anti-Aging Peptides: Monographs
• Chapter 18. Cognitive, Mood and Sleep Peptides: Monographs
• Chapter 19. Skin, Hair and Aesthetic Peptides: Monographs
• Chapter 20. Sexual Health and Hormone Peptides: Monographs (you are here)
• Chapter 21. Immune and Inflammatory Peptides: Monographs
• Chapter 22. Industry, Market and Research Developments

Previous: Chapter 19. Skin, Hair and Aesthetic Peptides: Monographs

Next: Chapter 21. Immune and Inflammatory Peptides: Monographs